Sexually Transmitted Infections in Women: Screening and Treatment

Sexually transmitted infections (STIs) affect an estimated 26 million people annually in the United States, according to the Centers for Disease Control and Prevention (CDC), with women bearing a disproportionate burden of long-term complications including pelvic inflammatory disease, infertility, and increased cervical cancer risk. This page covers the major STI categories relevant to women's health, how screening and diagnostic mechanisms function, the clinical scenarios that drive testing decisions, and the criteria that distinguish routine from urgent care pathways. Understanding these boundaries is foundational to any complete picture of women's health, particularly for those navigating preventive care across reproductive life stages.

Definition and Scope

STIs are infections transmitted primarily through sexual contact — including vaginal, anal, and oral routes — caused by bacteria, viruses, or parasites. The CDC recognizes more than 30 distinct pathogens transmissible through sexual contact, though a smaller group accounts for the majority of clinical burden in women:

Chlamydia is the most frequently reported notifiable condition in the United States (CDC STI Surveillance 2022), with 1.6 million cases reported in 2022 — a figure that substantially undercounts true prevalence due to asymptomatic presentation.

Women are biologically more susceptible to bacterial and viral STI acquisition per exposure event than men, owing to the larger mucosal surface area of the vaginal epithelium and the relative fragility of cervical tissue, particularly among adolescents and young adults. This susceptibility gradient, documented in CDC and WHO literature, underpins why screening recommendations are structured differently by sex.

The regulatory framing governing STI screening and treatment in the United States spans multiple agencies. The U.S. Preventive Services Task Force (USPSTF) issues evidence-based Grade A and B recommendations — including mandatory coverage requirements under the Affordable Care Act (ACA) for preventive services — for chlamydia, gonorrhea, syphilis, and HIV screening. The broader regulatory context for women's health shapes how these mandates translate into insurance coverage obligations.

How It Works

Screening Mechanisms

STI screening in women relies on four primary diagnostic modalities:

  1. Nucleic Acid Amplification Tests (NAATs): The gold standard for chlamydia, gonorrhea, and trichomonas. Vaginal swabs (self-collected or clinician-collected) demonstrate sensitivity exceeding 95% for chlamydia and gonorrhea per USPSTF and CDC guidelines. Urine-based NAATs are also validated for these pathogens.
  2. Serologic testing: Used for HIV, syphilis, herpes simplex (HSV-2 IgG), and hepatitis B. The standard HIV screening algorithm combines a fourth-generation antigen/antibody combination immunoassay with supplemental confirmatory testing per CDC laboratory testing guidance.
  3. Visual and microscopic examination: Trichomonas vaginalis can be identified via wet mount microscopy, though NAAT is more sensitive. HPV is detected through co-testing with Pap smear cytology or as a primary screening modality from cervical cells.
  4. Culture: Less common for gonorrhea now that NAATs dominate, but essential when antibiotic resistance profiling is required.

Treatment Frameworks

Treatment is pathogen-specific and guided primarily by CDC's Sexually Transmitted Infections Treatment Guidelines, 2021:

Partner notification and expedited partner therapy (EPT) — allowing clinicians to prescribe treatment for sexual partners without requiring a clinical visit — is legally permitted in 47 states as of 2023, per CDC EPT data.

Common Scenarios

Asymptomatic young adult: A sexually active woman under age 25 with no symptoms. USPSTF issues a Grade B recommendation for annual chlamydia and gonorrhea screening for all sexually active women under 25, regardless of symptom status. This group carries the highest prevalence burden — women aged 15–24 account for approximately 43% of all reported chlamydia cases nationally (CDC 2022 Surveillance).

Pregnancy: Syphilis, HIV, hepatitis B, and chlamydia screening are recommended at the first prenatal visit for all pregnant women (USPSTF Grade A for each). Gonorrhea screening is recommended for those at elevated risk. Untreated syphilis in pregnancy carries a vertical transmission risk that can cause stillbirth, neonatal death, or congenital syphilis — a condition that reemerged as a public health concern, with the CDC reporting 3,761 congenital syphilis cases in 2022.

Postmenopausal woman with a new partner: Risk assessment drives testing frequency; USPSTF does not apply a blanket age ceiling, and HIV screening is recommended at least once for all adults aged 15–65 irrespective of self-assessed risk.

HPV and cervical cancer screening integration: Women aged 21–65 follow cervical cancer screening protocols that intersect directly with HPV detection; this overlap is detailed further in the cervical cancer screening and HPV resource.

Decision Boundaries

Distinguishing routine screening from urgent evaluation depends on symptom profile, exposure history, and test result patterns.

Routine screening pathway applies when:
- No acute symptoms are present
- Testing is interval-based per USPSTF, CDC, or obstetric care guidelines
- Results are processed through standard laboratory turnaround (24–72 hours typical for NAAT)

Urgent evaluation is indicated when:
- Symptoms suggest pelvic inflammatory disease (PID): lower abdominal pain, cervical motion tenderness, fever above 38.3°C — PID can result in permanent tubal damage from a single untreated episode
- A reactive syphilis screen accompanies neurologic or cardiovascular symptoms
- HIV status is unknown following a high-risk exposure event (post-exposure prophylaxis, or PEP, must be initiated within 72 hours of exposure per HHS PEP guidelines)
- Gonorrhea NAATs are positive and the patient is pregnant, immunocompromised, or disseminated infection is suspected

Resistance and treatment failure boundaries:
Gonorrhea is the STI of greatest antimicrobial resistance concern. The CDC's Antibiotic Resistance Threats in the United States, 2019 classifies drug-resistant Neisseria gonorrhoeae as an "urgent" threat — the highest category. Treatment failure after ceftriaxone should prompt culture with susceptibility testing and consultation with local public health authorities.

Distinguishing STI from non-STI vaginitis: Bacterial vaginosis (BV) and vulvovaginal candidiasis are not classified as STIs but produce overlapping symptoms (discharge, odor, irritation). Distinguishing them from trichomoniasis — which is sexually transmitted — requires NAAT or wet mount; empiric treatment without testing risks misclassification. This distinction is part of broader pelvic and urinary tract health in women frameworks.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)